FC
CLDX icon

FORA Capital’s Celldex Therapeutics CLDX Stock Holding History

FORA Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,115
Closed -$317K – 548
2022
Q4 		$317K Buy
+7,115
New +$254K 0.05% 349
2021
Q3 		– Sell
-9,861
Closed -$330K – 454
2021
Q2 		$330K Buy
+9,861
New +$271K 0.06% 346

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FORA Capital's CLDX Position: Q1 2023 in Review

FORA Capital sold out of Celldex Therapeutics (CLDX) in Q1 2023, closing a stake of 7,115 shares — an estimated $317K sold.

FORA Capital first reported a position in CLDX in Q2 2021 and held it in 2 quarters. The position peaked at $330K in Q2 2021. 161 funds tracked by Wall St. Rank hold CLDX as of Q1 2023.

  • FORA Capital reported no remaining Celldex Therapeutics position as of Q1 2023 after selling out during the quarter.
  • FORA Capital sold 7,115 Celldex Therapeutics shares in Q1 2023, an estimated $317K.
  • FORA Capital first reported a position in Celldex Therapeutics in Q2 2021 and held it in 2 quarters.
  • FORA Capital's Celldex Therapeutics position peaked at $330K in Q2 2021.
  • 161 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2023.

Based on FORA Capital's 13F filing for Q1 2023, filed 12 May 2023.